ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth

Product gross successful the 4th was up 168% twelvemonth implicit twelvemonth to $44.2 million. The summation comes connected the heels of ANKTIVA, an FDA-approved attraction for non-muscle invasive bladder cancer, commercialized launch. The important merchandise gross builds connected 2025 nett merchandise gross of $113 million, a 700% summation implicit 2024. ImmunityBio exited the 4th with $380.9 cardinal successful currency and currency equivalents.

ANKTIVA is the company’s pb product, expected to solidify its gross basal arsenic it has been approved crossed 5 jurisdictions representing 34 countries. Its continued momentum underscores increasing doc adoption and disciplined commercialized execution. Following beardown maturation successful 2025, ImmunityBio is focused connected scaling successful the US and expanding into planetary markets to prosecute caller gross streams.

ImmunityBio, Inc. (NASDAQ:IBRX) is simply a clinical-stage biotechnology institution focused connected processing and commercializing next-generation immunotherapies that activate a patient’s earthy slayer (NK) cells and T cells to dainty cancers and infectious diseases. Its pb FDA-approved drug, ANKTIVA (N-803), is utilized successful operation with BCG to dainty non-muscle invasive bladder crab (NMIBC).

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy successful 2026.

Disclosure: None. Follow Insider Monkey connected Google News.